Nutra Pharma Corp. Reports Decrease in Q3 Net Sales and Increased Losses

Nutra Pharma Corp. reported its financial results for the third quarter ending September 30, 2025, revealing a net sales figure of $70,242, a decrease from $74,994 in the same quarter of the previous year. For the nine-month period, the company generated $228,748 in net sales, up from $164,436 in the prior year. Despite this increase in sales for the nine-month period, Nutra Pharma experienced a net loss of $523,520 for the third quarter, compared to a loss of $260,683 in the same quarter of 2024. The cumulative net loss for the nine months reached $1,558,866, significantly higher than the $1,054,756 loss reported for the same period last year.

The company's operating expenses surged to $420,652 for the third quarter, up from $255,445 in the prior year, contributing to the increased losses. The rise in expenses was attributed to higher selling, general, and administrative costs, which totaled $1,204,959 for the nine months, compared to $860,289 in 2024. Nutra Pharma's accumulated deficit also grew to $77,790,003 as of September 30, 2025, reflecting ongoing financial challenges.

In terms of operational developments, Nutra Pharma's total current assets increased to $545,106, up from $374,837 at the end of 2024. This growth was driven by a rise in accounts receivable and other receivables, including a notable increase in accounts receivable from related parties, which rose to $18,984 from $5,800. However, the company continues to face significant liabilities, with total current liabilities amounting to $16,923,083, up from $15,267,192 at the end of the previous fiscal year. The stockholders' deficit also widened to $16,350,780, compared to $14,807,914 at the end of 2024.

Looking ahead, Nutra Pharma's management expressed concerns regarding the company's ability to continue as a going concern, citing a working capital deficit and the need for additional financing to sustain operations. The company is currently reliant on debt and equity funding, but has faced challenges in raising sufficient capital. Nutra Pharma's common stock is listed on the OTC Market Group’s Expert Market, which limits its ability to attract investment. The company plans to secure adequate funding through notes payable until its sales of pain products can sufficiently support operations. The outlook remains uncertain, contingent on the company's ability to increase revenues and manage its financial obligations effectively.